St. Jude Medical halts the Enlightn IV trial of its renal denervation technology just a few months after getting the green light to begin enrollment.
St. Jude Medical (NYSE:STJ) is calling off the Enlightn IV trial of the next generation of its renal denervation technology, just a few months after it began.
Ablative Solutions says it's pulled in an $8 million funding round for its perivascular renal denervation technology for treating high blood pressure.
Ablative Solutions, which is developing perivascular renal denervation technology for treating high blood pressure, raised an $8.0 million funding round, according to a regulatory filing.
Menlo Park, Calif.-based Ablative Solutions said 98 unnamed investors participated in the funding round, which consisted of debt, options and warrants.
Medtronic enrolls the 1st patient in an FDA-approved clinical trial evaluating renal denervation in treatment of patients with less-severe drug-resistant hypertension.
Medical device giant Medtronic (NYSE:MDT) is making fast work of its U.S. renal denervation program, today announcing FDA approval to begin enrolling lower-risk patients in the next phase of its SYMPLICITY clinical trials.
Kona Medical raises a $10 million Series D round for its renal denervation device as it turns its eye toward China.
Kona Medical said it closed a $10 million Series D round it plans to use to enter the Chinese renal denervation market.
Unlike other renal ablation systems, Kona's Surround Sound device uses external ultrasound to non-invasively target the nerves leading to and from the kidney
Cardiosonic closes out a 1st-in-human trial of its Tivus renal denervation device for treating high blood pressure and launches a 2nd study.
Cardiosonic Ltd. said it's completed a 1st-in-human trial of its Tivus renal denervation device and has launched a 2nd trial.
The Tel Aviv-based medical device company is developing the Tivus device to treat high blood pressure using renal denervation. Unlike other renal denervation technologies that use radiofrequency energy to ablate the nerve lining the renal arteries, the Tivus device uses ultrasound waves.
California medical device maker Sotera Wireless touts FDA clearance a new feature of its ViSi Mobile continuous blood pressure monitoring system.
MASSDEVICE ON CALL — Sotera Wireless this month touted FDA clearance for a new feature of its ViSi Mobile continuous non-invasive blood pressure system, now able to monitor patients without the use of a catheter or blood pressure cuff.
The novel new device has long been part of Sotera's product portfolio, but wasn't cleared alongside earlier ViSi Mobile systems.
Many of the medtech industry's biggest players have put large stakes in renal denervation as a new device-based option for patients with drug-resistant hypertension, but the global barriers to adoption may be taking some of the shine off this much-hyped market.
MASSDEVICE ON CALL — Renal denervation has been among the hottest new areas for medical device research & development, but the time and money put in has yet to pay off in a big way, according to medtech analyst Joseph Gregory.
Renal denervation hogged headlines and spotlights at conferences around the world last year, but the message in 2013 is a much more sober one: the technology hasn't taken off as quickly as the industry might have hoped.